Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CyGene Laboratories has announced that it is introducing StrokeScan, a genetic screening test aimed at identifying high risk individuals who have a family history of stroke, cardiovascular or kidney disease.
Subscribe to our email newsletter
CyGene’s StrokeScan analyzes genes that have been associated with the increased risk of stroke and the ‘alpha-galactosidase A’ gene that is responsible for Fabry disease.
The StrokeScan is said to be based on know-how and intellectual properties that CyGene exclusively licensed from Arndt Rolfs of the University of Rostock, Germany.
Martin Munzer, president and CEO of CyGene, said: “StrokeScan has the ability to save lives. Genetic screening of people in high risk groups is essential in order to identify and then diagnose Fabry disease accurately and at an early stage.”